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Abstract
The study of drug toxicity in human organs is complicated by their complex inter-relations
and by the obvious difficulty to testing drug effects on biologically relevant material. Animal
models and human cell cultures offer alternatives for systematic and large-scale profiling of
drug effects on gene expression level, as typically found in the so-called toxicogenomics
datasets. However, the complexity of these data, which includes variable drug doses, time
points, and experimental setups, makes it difficult to choose and integrate the data, and to
evaluate the appropriateness of one or another model system to study drug toxicity (of par-
ticular drugs) of particular human organs. Here, we define a protocol to integrate drug-wise
rankings of gene expression changes in toxicogenomics data, which we apply to the TG-
GATEs dataset, to prioritize genes for association to drug toxicity in liver or kidney. Contrast
of the results with sets of known human genes associated to drug toxicity in the literature
allows to compare different rank aggregation approaches for the task at hand. Collectively,
ranks from multiple models point to genes not previously associated to toxicity, notably, the
PCNA clamp associated factor (PCLAF), and genes regulated by the master regulator of
the antioxidant response NFE2L2, such as NQO1 and SRXN1. In addition, comparing gene
ranks from different models allowed us to evaluate striking differences in terms of toxicity-
associated genes between human and rat hepatocytes or between rat liver and rat hepato-
cytes. We interpret these results to point to the different molecular functions associated to
organ toxicity that are best described by each model. We conclude that the expected pro-
duction of toxicogenomics panels with larger numbers of drugs and models, in combination
with the ongoing increase of the experimental literature in organ toxicity, will lead to increas-
ingly better associations of genes for organism toxicity.
Introduction
Therapeutic drugs, industrial and environmental chemicals, and other compounds can have
undesired toxic effects in diverse parts of the human body. This might be due to their direct
interaction with cell components, but also, if they are metabolized, due to effects of their
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downstream catabolism [1]. These direct and indirect effects depend on the tissues considered
(e.g., hepatotoxicity in liver [2] or nephrotoxicity in kidney [3]), on the human individual
genetic variation (e.g., if a catabolizing enzyme has variable specificity associated to a single
nucleotide polymorphism [4]) and on environmental factors (e.g., interaction with nutrients
[5]). Thus, the toxic effects a given compound exerts in a given organ are a result of very com-
plex interactions at cellular, organismic and environmental level, involving often multiple tox-
icity mechanisms [6].
The organ-specific study of drug effects on human physiology, while necessary, is however
difficult given the impossibility of systematically testing the human system. Therefore, the
commonly established approaches in the field of drug development and toxicology rely on
studies of drug effects in animal organisms (in vivo) or in cultivated animal and human cell
lines (in vitro). Profiling of gene expression can inform at a very detailed level about the effects
of drugs. With the advent of high throughput technologies (in particular, the cost-effective
microarrays), genome-wide transcription profiles of specific drug effects have been captured
across multiple organs or cell types, drug dose levels and drug treatment time intervals. This
enabled toxicologists to study the biochemical and biological mechanisms affected by a specific
drug as well as the mechanisms behind organ-specific and general drug-induced toxicity. Most
importantly, large-scale initiatives (e.g., DrugMatrix by Iconix Biosciences [7], the Japanese
toxicogenomics project [8] and the EU funded InnoMed PredTox project [9]) have produced
highly controlled and standardized toxicological experiments with rodent organisms (rat and
mouse) and rodent and human cell lines, for hundreds of chemicals, resulting in comprehen-
sive toxicogenomics resources for systematic analysis of drug induced toxicity effects, such as
DrugMatrix [7], CMap [10] and Open TG-GATEs [11].
In this respect, the aim of the recently established field of toxicogenomics is to integrate
these rapidly expanding collections of data (including gene expression profiles, clinical chem-
istry measurements, histopathology assessment data and curated literature annotations) in
order to identify more specific and sensitive human toxicity biomarkers that should lead to
more accurate toxicity detection at early stage of drug development and ultimately to safe mar-
keted drugs [12].
While their contribution to our understanding of drug-induced toxicity is undeniable, one
fundamental question that is difficult to address comprehensibly regarding the different sys-
tems used for experimentation in toxicogenomics studies is how reliably the specific animal
organism, model system (in vivo or in vitro), reflects the toxicity effects of drugs for a given
human organ in terms of genes (or molecular functions) whose expression is affected. In par-
ticular, it would be desirable to have a protocol to evaluate the appropriateness of multiple
model systems so that the optimal one can be chosen for each organ, depending on the ability
of the given model to affect the expression of genes and functions of interest.
Here, we describe a method to obtain lists of ranked genes according to gene expression
changes in a toxicogenomics dataset profiling gene expression changes upon multiple drugs,
conditions, and time points. If the dataset uses a particular tissue or cellular line as model to
test drug toxicity, the expectation is that the ranked list reflects genes generally associated to
toxicity in this model. Because our goal is to model toxicity in human organs, if the model is
non-human, we take the corresponding human orthologous genes. Then, we optimize the
methodology and parameters to obtain this ranking by comparison to the set of genes already
known to be associated to drug toxicity in the corresponding organ in the literature.
Due to the multi-factorial experimental designs of the existing toxicological databases, we
need to integrate data across multiple model systems, drugs, dose levels and time points. A rel-
atively simple way is to summarize the genome-wide drug-induced transcriptional changes in
prioritized (ranked) gene lists, followed by a rank-aggregation approach [13] to combine them
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into a single organ-specific gene list. While this approach is commonly used for prioritization
of disease-related genes [14], here we use it as baseline method for prioritization of toxicity-
related genes. In particular, we exploit the robustness (with respect to noise, outliers and errors
in the data to be aggregated) and computational efficiency of recently proposed probabilistic
methods for rank-aggregation, i.e., RRA [15] and BIRRA [16].
We applied this approach to a toxicogenomics dataset corresponding to 33 compounds
(mainly toxic drugs) profiled in primary human hepatocytes, primary rat hepatocytes, rat liver
(as models for hepatotoxicity) and rat kidney (as model for nephrotoxicity), obtained from the
Open TG-GATEs database. The latter was especially suitable for our purposes due to the con-
sistent experimental design applied across the four model systems. We evaluated multiple
ways to aggregate these data for the description of drug-induced toxicity in human kidney and
liver.
In doing this analysis, we discovered some genes that while ranking very high and very
often in response to liver and kidney drug toxicity, have not been yet mentioned in the litera-
ture in relation to toxicity. These could be potentially working in novel toxicity-related path-
ways. We discuss the striking differences observed between human and rat hepatocytes, and
the insight that can be gained into which processes can be modelled when using cell lines (rat
hepatocytes) versus entire organs (rat liver). We use these results to describe the suitability of
each of these models to study different molecular functions associated to organ toxicity
according to the sets of genes whose expression is affected.
Methods
Unless otherwise stated, the complete protocol for data analysis was performed using the R
version 3.2 computing environment [17] and packages from the open-source software devel-
opment project Bioconductor version 3.1 [18].
Toxicogenomics data collection
The data used in this study originate from the Open Toxicogenomics Project-Genomics
Assisted Toxicity Evaluation System (TG-GATEs) database established during the Japanese
Toxicogenomics Project [8]. This large-scale public toxicogenomic resource stores microarray
gene expression and toxicological profiles of in vivo (rat liver and kidney) and in vitro (primary
cultured rat and human hepatocytes) biological samples exposed to 170 different chemical
compounds [11]. The experimental design involved at least two biological replicates per exper-
iment (three in the in vivo experiments), compound administration at different dose levels
(low, middle and high, as well as a vehicle control corresponding to no compound administra-
tion) and time measurements taken in two different scenarios (single-dose and repeated-
dose). The single-dose scenario included up to four measurements taken after single com-
pound dose administration (at 2, 8 and 24 hours in the in vitro and at 3, 9, 12 and 24 hours in
the in vivo experiments, respectively); the repeated-dose scenario included single dose admin-
istration per day per rat, and measurements were taken at 4, 8, 15 and 29 days. The gene
expression of the obtained samples was profiled with two Affymetrix GeneChip arrays: Rat
Genome 230 2.0 (rat samples) and Human Genome U133 Plus 2.0 (human samples).
In order to have fair comparison across the model systems, we used the gene expression
profiles corresponding to a subset of 33 compounds, with a compound being selected if it was
used in the single-dose experiments across all model systems, i.e., human hepatocytes (HH),
rat hepatocytes (RH), rat liver (RL) and rat kidney (RK). Among the selected compounds
(listed in S1 File), we found 26 drugs with diverse therapeutic use (e.g., the widely used analge-
sic acetaminophen, the antifungal ketaconazole and the antibacterial rifampicin) and 7
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environmental toxicants (allyl alcohol, bromobenzene, bromoethylamine, ethionine, hexa-
chlorobenzene, monocrotaline, and thioacetamide). Except for caffeine, all compounds are
classified in the literature as hepatotoxic or nephrotoxic (including the ones being carcino-
genic for the liver or the kidney), with 20 compounds harmful for both kidney and liver (e.g.,
the gout-related agent allopurinol, the anti-inflammatory indomethacin, the antibacterial
nitrofurantoin and the carcinogenic thioacetamide). While the majority of drugs belong to the
enzyme inhibitor class in terms of mode of action (that defines how the compound affects the
molecular target), these compounds are more diverse in terms of physiochemical properties.
More precisely, only acetaminophen, bucetin and phenacetin cluster together after binning
clustering with 0.4 cut-off for compound similarity in the web tool ChemMine [19]. The com-
pound similarity was defined by the Tanimoto similarity coefficient, also known as Jaccard
index [20], and calculated using the Open Babel molecular descriptors for the compounds.
The latter were calculated also in ChemMine based on the compound structure representa-
tions in simplified molecular input line entry system (SMILES) as provided in S1 File.
While the full experimental design is available for the rat samples, gene expression profiles
for 15 compounds were not conducted for the low dose level or for the earliest time point in
HH. The raw gene expression data in .CEL Affymetrix file format and the corresponding meta-
data file (with the GeneChip code, experiment-description features and toxicological data)
were downloaded from the archived site [21].
Microarray data preprocessing
The .CEL files corresponding to the selected compound treated samples were processed in
four batches with 623 HH, 792 RH, 1584 RL and 1584 RK samples, respectively. The probe
intensity data were mapped to probesets expression data with the Robust Multiarray Average
(RMA) algorithm [22], which combines convolution background correction, quantile normal-
ization and median-polish-based multiarray summarization, as implemented in the package
affy version 1.46.1. This step delivered estimate expression values for 54,675 and 31,099 probe-
sets per profiled sample with the Human Genome U133 Plus 2.0 and the Rat Genome 230 2.0
arrays, respectively. These were furthermore filtered to remove non-specific probesets map-
ping to multiple gene NCBI Entrez IDs, and to select a single probeset per gene. The latter was
done by choosing the most variant probeset across all model system-specific conditions when-
ever multiple probesets mapped to one gene. The most variant probeset was defined to be the
one with the largest interquartile range of expression values across all samples for a given
model system, possibly the most informative. While this approach can be problematic when
probesets represent multiple gene transcripts that are expressed at very different levels, it is
commonly used as it provides a single result per gene. This step resulted in 20,390 human pro-
besets, and 14,517 rat probesets annotated with a unique NCBI Entrez ID. Probesets’ annota-
tions with gene symbols and IDs were obtained with the corresponding metadata packages:
hgu133plus2.db version 3.1.3 (Human Genome U133 Plus 2.0 arrays) and rat2302.db version
3.1.3 (Rat Genome 230 2.0 arrays).
Differential expression analysis
For each model system, we performed compound-wise analysis of differential expression (DE)
with the Microarray Significant Profiles (maSigPro) method, implemented in the package
maSigPro version 1.40.0 [23]. maSigPro is a two-step regression method that models the
dynamic nature of gene expression by fitting a global polynomial model of time with dummy
variables used to encode different experimental groups. The first regression step essentially
finds statistically significant gene models, i.e., genes that show change over time in at least one
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experimental group (including the control group) or treatment-dependent expression. The
second step uses stepwise regression to adjust the model coefficients of the significant gene
models in order to find significant differences among the experimental groups, in particular
among the treatment and the control groups. We selected differentially expressed genes with
the following parameter setup: (i) global polynomial model with up to cubic time effect (due to
the four time measurements) and three dummy variables (one for each dose level), (ii) P-
value� 0.01, 0.01 cut-off for the P-value associated to the F-test statistics in the global model,
after adjustment with the false discovery rate (FDR) method by Benjamini and Hochberg [24],
(iii) two-way backward stepwise regression with P-value� 0.05/n (coefficient-related P-value
in the adjusted models, with n being number of model coefficients), and (iv) R2� 0.6, at least
60% of gene expression variance explained by the adjusted gene model.
Genes selected by this method are the ones that show variations in differential expression
(versus control cases) over time. We applied ARSyN noise removal on the compound-specific
expression matrix before applying maSigPro following the strategy suggested by Nueda et al.
[25].
Gene ranking
To enable cross-organism comparison we analyzed the differential gene expression of the
12,037 protein-coding genes that have a one-to-one mapping between human and rat as
defined in the NCBI HomoloGene version 68 database [26].
The genes profiled on the human or rat arrays were ranked independently for each com-
pound and model system according to the results from maSigPro: (i) all genes that did not
pass the F-test were given the same lowest rank, (ii) the rest were ranked by R2 of the adjusted
model with ties resolved by the P-value of the adjusted model, and (iii) the genes that after
model adjustment had no significant model coefficient were also given the same lowest rank.
The resulting ranking is technically an extended partial ranking.
We applied several rank aggregation methods to obtain a single rank for each of the 12,037
genes across all 33 compounds in each given model system.
Probabilistic methods used for rank aggregation. Robust Rank Aggregation (RRA) is a
parameter-free method that provides a significance score (P-value) for the calculated rank
[15]. Assuming the genes of interest will be highly ranked across many toxic compounds
(informative ranks) and ignoring the noise from the small portion of non-toxic compounds
(non-informative ranks, including possible outliers), RRA models the informative normalized
ranks as sampled from a zero-skewed distribution. It calculates a score for a single gene at a
time, by comparing the sorted compound-specific normalized ranks for the given gene to a
fixed null model of uniformly-random distributed normalized ranks. The latter results in the
assignment of a P-value for each sorted compound-specific rank, and the minimal P-value
across all compounds (after Bonferroni adjustment for multiple comparisons across com-
pounds) is used as the gene-associated score. This score is actually used to re-rank all the input
genes and at the same time it represents a significance score (P-value) showing how much bet-
ter a gene was ranked than expected by chance. STUART, the predecessor of RRA, is less com-
putationally efficient and does not provide rank significance [14, 27]. Bayesian Inference
Robust Rank Aggregation (BIRRA) implements rank aggregation via Bayesian reasoning [16].
The method assumes that there is a latent signal to be discovered and this is represented with
varying reliability (weight) in the datasets to be integrated. In our case, for example, gene lists
from toxic compounds should contribute more (relative to the non-toxic compounds) to the
aggregated list, assuming there exist (hidden) toxicity-related traits that are contributed by a
common set of genes across organ-specific toxic compounds. The weights are directly
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estimated from the data in the form of Bayes factors: starting with an equally weighted consen-
sus generated by rank averaging, BIRRA iteratively fits Bayes factors to each dataset and
recomputes the rank aggregation until either there are no changes in the rankings or the maxi-
mum number of iterations is exceeded.
Ad-hoc rank methods used for comparison. We further used aggregation based on sim-
ple average of ranks (MEAN), rank by the number of compounds that modulated the gene
(NC), and finally, the median of the aggregated ranks RRA, MEAN, STUART, BIRRA, and
NC (AR).
We used RRA and STUART as implemented in the package RobustRankAgregg version
1.1. The same also implements the significance score for the MEAN rank. The MEAN/RRA P-
values were additionally corrected for multiple testing with the FDR method by Benjamini and
Hochberg [24] before using them for gene ranking. The R source for BIRRA was downloaded
from the author’s site [28] and was applied with default parameter values (number of bins set
to 50, maximum number of iterations set to 10 and prior probability of the positive class set to
0.05). Finally, all tie cases (same value of the ranking criteria) were resolved by assigning equal
rank calculated as average of the default-assigned ranks by the ordering procedure.
Toxicity-related genes from the literature
To evaluate and optimize the ranks for the prioritization of toxicity relevant genes from the
toxicogenomics dataset we collected genes discussed in the literature in relation to organ-spe-
cific (liver or kidney) toxicity.
The publicly available PubMed annotations [26] were used for prioritizing gene candidates
related to the topics of liver or kidney-related human toxicity. This was performed as a gene-
topic co-occurrence analysis in PubMed abstracts (see below for details). The statistical signifi-
cance of each gene-topic association was measured by the one-tailed Fisher’s exact test [29].
Only human protein-coding genes were tested. The background set was the same in all tests,
and was defined by the complete set of PubMed abstracts written in English. The subset of
abstracts corresponding to each human gene (manually annotated by NCBI curators) was
extracted from gene2pubmed and GeneRIF files [30]. Furthermore, the toxicity-related
abstracts were filtered by organ and defined as the set of PubMed abstracts obtained by the fol-
lowing PubMed search queries: (i) “nephrotoxicity OR [toxicity AND kidney]”, and (ii) “hepa-
totoxicity OR [toxicity AND liver]”. Note that the queries aim to capture all abstracts related to
organ-specific toxicity and not only drug-induced organ-specific toxicity.
Gene-topic association-wise Fisher’s exact test statistics were adjusted with the FDR
method by Benjamini and Hochberg [24]. Genes with topic-association both under the 0.05
cut-off and supported with at least three PubMed abstracts were selected as literature candi-
dates. After subsequent filtering for genes that have a one-to-one rat ortholog in the NCBI
HomoloGene v.68 database [26], we finally obtained 48 and 21 literature gene candidates for
hepatotoxicity and nephrotoxicity, respectively. Both lists were subjected to disease enrich-
ment analysis to verify the biological relevance for human toxicity. This was performed with
the Gene Set to Diseases (GS2D) web tool [31]. The results were filtered at 0.05 FDR.
ROC analysis
To evaluate the rankings obtained by the different methods for toxicity gene prioritization we
calculated the receiver-operating characteristic (ROC) curve and the Area Under the ROC
Curve (AUC), using the literature-derived toxicity genes as positive examples and all the
remaining genes from the full list of ranked genes as negative examples. Calculations were per-
formed with the package pROC version 1.8 [32].
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Rank correlation analysis
We used Spearman’s rho, a nonparametric correlation coefficient, to assess statistical associa-
tions between two lists with gene-wise ranks. Spearman’s rho has values between -1 and 1,
with positive correlation values indicating similar (or identical for correlation of 1) gene ranks
in both lists, while negative values indicate dissimilar (or fully opposed for a correlation of -1)
ranks in both lists. The correlation values, including the test for no association, were calculated
with the package stats version 3.2.3 [17].
Visualization
Most of the figures were generated with the packages ggplot2 version 2.1.0 [33] and graphics ver-
sion 3.2.3 [17]. The plots visualizing the modules and their overlaps are generated with the cus-
tomized heatmap function [34], while module regulatory networks were visualized with GePS.
Functional enrichment analyses
To assess the significance of functional enrichment in ranked lists of genes, we used the g:Pro-
filer web tool (here, with the top 100 genes; [35]). This tool computes the over-representation
of functional terms in the ranked list of genes. The terms assessed were from the Gene Ontol-
ogy (GO) hierarchy: biological process (BP), molecular function (MF) and cellular compo-
nents (CC), and we also considered terms from the KEGG (keg) and REACTOME (rea)
pathway databases, CORUM protein complexes (cor), TRANSFAC binding sites (tf), and
Human Protein Atlas (hpa). GO terms were hierarchically filtered to best per parent.
Results
To develop a protocol for gene prioritization according to organ-specific toxicity from large-
scale panels of toxicogenomics profiles, we integrated microarray gene expression time series
from the Open TG-GATEs database [11] corresponding to 33 compounds (the majority of
which are nephrotoxic or hepatotoxic drugs, S1 File) for four model systems: human hepato-
cytes (HH), rat hepatocytes (RH), rat liver (RL) and rat kidney (RK). We chose to analyze HH,
RH, and RL to be able to compare multiple models for hepatotoxicity (in vivo versus in vitro,
and in human versus rat), and then added RK as model for nephrotoxicity, to be able to com-
pare results for two different in vivo models (liver versus kidney).
After microarray preprocessing and gene expression modeling, we performed a differential
analysis to identify genes with significant differential expression profiles over time for each
compound and model system. This step was crucial for the protocol as it provides the com-
pound-specific gene ranks that serve as input for the rank-aggregation step.
Using different rank-aggregation methods, compound-wise gene rankings were summa-
rized into one ranked gene list, which was limited to one-to-one orthologs between human
and rat (see Methods, subsection Gene ranking for details). We evaluated the performance of
the rank-aggregation methods against human liver and kidney toxicity-related genes derived
from co-occurrence analysis of PubMed abstract annotations (see Methods, subsection Toxic-
ity-related genes from the literature for details). We further compared the rank-aggregation
methods based on the receiver-operating characteristic (ROC) curve analysis, in order to select
the rank aggregation that shows better concordance with literature-derived toxicity genes (see
Methods, subsection ROC analysis for details). The optimal rank aggregation was used to gen-
erate four gene candidate lists, one for each model system, which were finally subjected to
functional enrichment analysis to evaluate the ability of the four models (HH, RH, RL, RK) to
recapitulate human organ-specific drug toxicity.
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Toxicity-related genes from literature
Based on 70,190 and 39,365 PubMed abstracts for liver and kidney toxicity, respectively, we
found 65 and 28 human protein-coding genes significantly associated with at least three toxic-
ity-related abstracts at 0.05 FDR, with ten genes common for both organs. Selection of genes
with orthologs in rat resulted in 48 and 21 genes for liver and kidney toxicity, respectively (see
Methods for details). Associations of these genes to disease related terms in the literature were
found to be significantly enriched in terms describing organ-specific injuries, such as acute
kidney injury, glomerulonephritis, renal insufficiency as well as drug-induced liver injury and
hepatocellular carcinoma. The hepatic toxicity list includes hepatotoxicity biomarkers such as
heme oxygenase (decycling) 1 (HMOX1), ATP binding cassette subfamily C member 2
(ABBC2), glutathione S-transferase alpha 1 and pi 1 (GSTA1 and GSTP1), keratin 18 (KRT18)
[36, 37]. The kidney toxicity list includes nephrotoxicity biomarkers such as kidney injury
molecule-1 (KIM1 or HAVCR1), lipocalin 2 (LCN2), and solute carrier family 22 member 6
(SLC22A6) [38]. The lists of genes (names and Entrez IDs) including PubMed IDs (PMIDs) of
the contributing abstracts are provided in S2 File.
Differential gene expression analysis
The overall analysis across the four model systems shows that the literature-derived toxicity-
related human genes are more often dys-regulated in the in vitro scenarios as compared to the
in vivo ones (Fig 1). On average, we have far more genes dys-regulated in both in vitro systems
(HH and RH) as compared to both in vivo systems (RL and RK), which might be a conse-
quence of isolation stress or because of the cell culture conditions as noted before by Godoy
et al. [39].
Furthermore, we observe a large discrepancy in the number of differentially expressed
genes across compounds, which shows good correlation with the increase of dose level (S1
Fig), and in many cases, also with the known toxicity label of the drug. For example, indometh-
acin is a known toxicant with high liver injury risk and shows high number of differentially
expressed genes in the hepatocyte and liver systems (S2 Fig). The same holds for the hepato-
toxic analgesic acetaminophen (commonly known as paracetamol), although we observe an
inconsistent pattern as well, e.g., known hepatotoxic drugs such as enalapril and valproic acid
dys-regulated ten (or more) times less genes in the RL than in the RH system.
Fig 1. Summary of differential expression analysis. Distribution of the number of differentially expressed genes is depicted with violin-plots by model
systems, with each dot representing the number of genes modulated by the high dose treatment with a single compound. The median and interquartile range of
each distribution is depicted by black squares and black bars, respectively. On the same plot, we illustrate the distribution of the full set (all), the filtered set with
unique human-rat orthologs (ortholog) and the subset found in the corresponding organ-specific literature-derived genes (literature).
https://doi.org/10.1371/journal.pone.0210467.g001
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Rank aggregation across compounds and scenarios
The ROC evaluation of the aggregation methods (Fig 2A, S3 Fig) across compounds suggests
that the rankings from models with largest numbers of differentially expressed genes recapitu-
late better the genes from the literature. Overall, in the in vitro scenario we get better perfor-
mance (larger AUC) as compared to the in vivo one. While the highly imbalanced size of
differentially expressed gene sets seems to affect the MEAN aggregation method the most, the
NC rank, which simply uses the number of compounds modulating a given gene, works in par
with the more complex aggregation methods. Due to the influence of the partial ranking, the
MEAN method and to a lesser extent the RRA method delivered often the same ranks for the
larger sets of genes; at the same time, the NC rank was quite high for these. The latter indicated
that we might benefit if we do second-level aggregation across the rank aggregation methods,
and one simple way is to go for the median of the aggregated ranks (named AR).
Evaluation of aggregation methods indicated that STUART was the optimal with AR very
close (Fig 2B). Since AR is an aggregation method, we preferred it for the final gene prioritiza-
tion. We selected the top 400 AR-ranked genes in each scenario for down-stream analysis.
The four rankings reflect how the four systems (HH, RH, RL, RK) respond to the same set
of toxic compounds and thus allow us to evaluate their strengths and their limitations in rela-
tion to each other in terms of recapitulating different aspects of human organ toxicity as
reflected in affected gene expression. The connection to genes allows the generation of hypoth-
eses about the concrete biological processes involved.
Examination of the highest 10 ranked genes (Table 1, columns HH, RH, RL, RK) shows no
overlap between models. A more meaningful result is obtained when fully comparing the four
rankings (Fig 3): the best correlation found is between RH and RL (Spearman’s rho = 0.61).
RH to HH is second best (Spearman’s rho = 0.49), which suggest that they certainly differ in
terms of response to toxic drugs, but not so much than when comparing other models (e.g.,
RK versus RL, Spearman’s rho = 0.28).
To find out about the processes affected by toxicity in each of the four models, we did func-
tional enrichment analysis of various terms for which the genes were annotated (including
Gene Ontology terms, pathways, participation in protein complexes, and tissue expression; see
Methods for details).
Interestingly, now the similarity between the top-100 genes of HH and RH is manifested in
terms of functional GO BP (Gene Ontology Biological Process) terms, where the most signifi-
cant are “carboxylic acid metabolic process” and “monocarboxylic acid metabolic process”,
respectively (see S5 and S6 Files). In both systems “response to drug” appears, although at a
less significant level.
A similar analysis for the top-100 genes of RL indicates terms related to cell cycle and cell divi-
sion (S7 File) indicating that the processes most affected are less specific when studying an organ.
In the case of RK we did not even obtain terms at high significance level (P-value< 1e-03; S8 File).
Combining the ranked gene lists for the four model systems
While the functional analysis above informs of the processes affected by toxicity in each of the
four models, we assume that the rankings can be meaningfully combined to better learn about
the similarities and differences between models. In the following paragraphs, we illustrate how
we can do this comparison (S4 File) and discuss the insight that can be gained.
Genes dys-regulated in the four model systems. To study genes dys-regulated in the four
systems we added the four rankings (column “all” in S4 File) and sorted the genes by value (see
top 10 genes in Table 1, column “all”). We would claim that these genes have functions consis-
tently related to toxicity because they are high in this aggregated ranking.
Literature optimized integration of gene expression for organ-specific evaluation of toxicogenomics datasets
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The top gene is HMOX1, selected from both of our literature analyses as kidney and liver
toxicity related. Other top genes include zinc finger, AN1-type domain 4 (ZFAND2A), PCNA
clamp associated factor (KIAA0101, now known as PCLAF or p15PAF), sulfiredoxin 1
(SRXN1; the only gene that appeared among the top 400 genes of each individual AR-ranked
list) and homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like
domain member 1 (HERPUD1). Both SRXN1 and HMOX1 are direct targets of the nuclear
factor, erythroid 2-like 2 (NFE2L2, also known as NRF2; which ranked among the top 400
genes in the three rat model systems, but very low in the human hepatocytes), a transcription
factor important for the coordinated up-regulation of genes in response to oxidative stress
[40]. Overexpression of KIAA0101 is associated to poor prognosis in several cancers, e.g.,
hepatic, primary lung [41], gastric [42], and esophageal [43]. The protein encoded by this gene
binds both to PCNA and to DNA and thus is assumed to have a function in the control of
DNA replication and repair [44].
The next two genes are cyclin-dependent kinase CDK1 and cyclin CCNA2 (see Table 1),
and in fact many cyclins and cyclin-dependent kinases are observed among the top 100 genes
(see S4 File). Using functional enrichment as above, confirmed cell cycle related enrichment
(S9 File). The most significant term for the GO BP category was “mitotic cell cycle” (22 genes
of top 62; P-value = 1.87e-12), “Cell cycle kinase complex CDC2” for CORUM (all 6 genes of
this category found among the top 89 in the list), “Cell cycle” for KEGG, and “Cell Cycle” for
REACTOME. The BP GO term “response to toxic substance” was highly significant too (16
genes among the top 65; P-value = 1.72e-08), followed close by the more general term “cellular
response to chemical stimulus” to which half the genes were related (40 genes of top 88; P-
value = 1.41e-07).
Terms explicitly related to response to drugs were found enriched only in HH and RH and
with worse P-values (“response to toxic substance”, 1.18e-05 and 7.8e-06, respectively). Collec-
tively, we took these results as an indication that this way of aggregating the ranks was useful
to point to genes and processes generally associated to toxicity in liver and kidney.
Fig 2. Performance comparison of gene ranking methods. A) ROC curves for compound-wise rankings (gray curves) and compound-
aggregated rankings (coloured curves) as calculated by the rank-aggregation methods, with literature-derived genes used as positive
examples. Curves are not smoothed, and the straight line fragments of the curves result from the initial partial ranking (same lowest rank
for all not-modulated genes, see Methods for details). B) Summary of AUC (area under the ROC curve) values for all rankings across all
model systems, including model system-wise median AUC represented as dashed line. AUC values above 50% means better
performance than randomly assigned rank.
https://doi.org/10.1371/journal.pone.0210467.g002
Table 1. Top 10 ranking genes for each model (HH, RH, RL and RK) and for combined rankings: Sum (all), and subtractions (HH>RH, RH>HH, RL>RH and
RH>RL). Font indicates toxicity association by literature, bold for liver, underlined for kidney.
HH RH RL RK all HH>RH RH>HH RL>RH RH>RL
GDF15 SELENBP1 CGN TRIM35 HMOX1 BCHE GSTP1 RPL14 SOX4
PDZK1IP1 CYP2C19 MAT1A DNAJB9 ZFAND2A SERPINA5 IDH1 DSP ID3
UPP1 C4BPB KIAA0101 MTHFR KIAA0101 MCHR1 ACTA1 CCNL2 AGXT2
NUSAP1 CYP1A2 INHBA USP2 SRXN1 TMEM138 CYP26B1 ACKR4 IDH1
PCK1 NNT TUBB IFRD2 HERPUD1 EFEMP1 SLC6A13 SLC25A32 CD276
DDB2 OTC UBE2C HSPA12A CDK1 HNMT PSCA SLC16A1 ACTA1
SLC2A2 FBP1 TMCC3 EIF2S2 CCNA2 LARP6 RBP4 CTPS1 FAM111A
FSTL1 GSTP1 SPC25 SLC17A3 UBE2C HADHA NXPE4 NIM1K CD14
TYMS PKLR TOP2A MAFF KIF20A C16orf45 AQP8 ABCB9 GC
HMOX1 AMPD3 CDO1 TMEM37 HMGCS2 PALM3 PXDC1 LIMS1 MAN2A1
https://doi.org/10.1371/journal.pone.0210467.t001
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Human versus rat hepatocytes. To evaluate differences between the two in vitro systems,
i.e., HH versus RH, we re-ranked the genes by a simple score calculated by subtracting the RH
rank from the HH rank (column “HH vs RH” in S4 File). A low value for the resulting score
highlights genes that changed in HH and not in RH, while a high value means the converse.
The top genes influenced by toxicity in HH but not in RH were BCHE, SERPINA5, MCHR1
and TMEM38 (see column “HH>RH” in Table 1). While this could be due to differences in
Fig 3. Comparison of AR-ranked gene sets across model systems. Rank correlation between the model system-specific gene rankings as measured by the
Spearman’s rho correlation coefficient.
https://doi.org/10.1371/journal.pone.0210467.g003
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the functions of these proteins, which could be reflected by differences in their sequences, this
was not always the case: TMEM138, transmembrane protein 138, is highly conserved between
rat and human (91% sequence identity), and so is BCHE, butyrylcholinesterase (79% sequence
identity).
At the other side of the list, we can see the genes that were highly affected by drugs in rat
hepatocytes but not in human: glutathione S-transferase pi 1 (GSTP1) and isocitrate dehydro-
genase (NADP+) 1 (IDH1) are at the top (column “RH>HH” in Table 1). The human IDH1is
100% identical to the rat ortholog. The case of GSTP1 is intriguing since both proteins in rat
and human are 210 amino acids long of which 180 are identical (85% sequence identity): the
human ortholog was not found to be differentially expressed in any of the 33 compounds for
the high dose case, while in rat hepatocytes it was found in 23 cases. Similarly, IDH1 was
selected as differentially expressed by 0 and 22 compounds for human and rat hepatocytes,
respectively. All these pairs of orthologs seem to have very similar lengths, and possibly
domain architectures. We conclude that the list indicates physiological differences.
Functional enrichment analysis did not suggest functions associated to these differences for the
top 100 genes affected in HH but not in RH (S10 File). Differently, the top 100 genes affected in
RH and not in HH were enriched in genes annotated with GO CC “extracellular exosome” (30 of
top 97; P-value = 1.67e-04), which is a very general category, and intriguingly, the most significant
GO BP was “retinoid metabolic process” (with 6 genes among top 84; P-value = 3.86e-03), among
them CYP26B1 and RBP4, which are among the top 10 (Table 1; S11 File).
Rat liver versus rat hepatocyte. Finally, we checked what different toxic responses we see
when looking for genes affected by drugs in rat liver but not in rat hepatocytes. For this purpose,
we compared RL with RH by subtracting the RH rank from the RL rank (see column “RL vs
RH” in S4 File) and re-ranking the genes by the resulting score (column “RL>RH” in Table 1).
Functional analysis indicated mostly genes expressed in glandular tissues (hpa terms; top one is
“endometrium; glandular cells”, 30 genes among top 73, P-value = 1.76e-04), and the most sig-
nificantly enriched GO BP term was “localization”, which refers to transport process (S12 File).
These genes would reflect processes involved in liver toxicity outside the hepatocyte.
At the other side of the list, we observed genes that could reflect hepatocyte-specific toxicity
mechanisms. As genes changing most in RH and less in RL we observed SOX4 and ID3
(Table 1). SOX4, sex determining region Y-box 4, is a transcription factor involved in the regu-
lation of embryonic development and in the determination of the cell fate. While this factor is
absent in normal adult liver, it has been recently shown that it plays an important function in
liver tumor metastasis [45]. ID3, inhibitor of DNA binding 3, dominant negative helix-loop-
helix protein, and other genes in the ID family have been noted to be down-regulated by iron
particles in hepatocytes [46]. Functional enrichment analysis indicated enrichment in genes
with GO CC term”extracellular exosome” (27 genes of top 63; P-value = 1.90e-07), but may be
more meaningfully, the most significant GO MF term was “lipid binding” (8 genes of top 19)
and two of the top 4 genes have the GO BP term “glioxylate metabolism” (AGXT2 and IDH1),
functions characteristic of the hepatocyte (S13 File).
In summary, S5 File collects the full ranks for the four models and allows the comparison of
toxicity responses in the four model systems considered. Scoring and sorting the genes com-
bined with enrichment analysis can be a powerful strategy to pinpoint differences and similari-
ties of toxicity responses in the four scenarios.
Discussion
Here, we presented a protocol to extract ranked gene lists from toxicogenomics datasets spe-
cific to model systems (e.g. human hepatocytes), which includes evaluation by agreement with
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the literature in human toxicity (e.g. dealing with human hepatotoxic genes). This approach
allows evaluating different ranking methods by the agreement of the resulting gene rankings
to the literature, and can be used to evaluate and compare the aspects of human toxicity reca-
pitulated by each system model.
Due to the multi-factorial experimental designs of the existing toxicological databases, we
needed to integrate data across multiple model systems, drugs, dose levels and time points. A
relatively simple way is to summarize the genome-wide drug-induced transcriptional changes
in a prioritized (ranked) gene list, followed by robust rank-aggregation approach [15] to com-
bine them into a single organ-specific gene list. While this approach is commonly used for pri-
oritization of disease-related genes [14], here we used it as baseline method for prioritization
of toxicity-related genes. In particular, we exploit the robustness (with respect to noise, outli-
ers, errors) and computational efficiency of recently proposed probabilistic models for rank-
aggregation, i.e., RRA [15] and BIRRA [16].
While the task of aggregating results from toxicogenomics datasets is clearly not trivial [3],
current research efforts show that carefully designed protocols for meta-analysis can poten-
tially address issues of heterogeneity of samples. For example, novel (more generic) gene bio-
markers for drug-induced toxicity have been identified by integration of differential
expression analysis and data mining of in vitro and/or in vivo toxicogenomics data [47, 48].
Several studies exploited biclustering methods [49] for coherent coexpression gene module
discovery combined with downstream functional enrichment analysis to characterize con-
served pattern of drug response across human cell lines [50] and prioritize gene modules for
specific chemically-induced liver [51] and kidney injury endpoints [52]. Last, but not least, El-
Hachem et al. [53] showed that mapping the drug-induced transcriptional changes in hepato-
cytes into the space of enriched biochemical pathways, combined with subsequent bi-cluster-
ing, reveals conserved modules of chemically modulated pathways in human hepatocytes, rat
hepatocytes and rat liver model systems.
Here, we focused on the evaluation of organ-specific toxicity-associated genes, and pro-
posed a protocol to prioritize genes that we evaluated with the literature data, with a focus on
kidney and liver. We applied this approach to a toxicogenomics dataset corresponding to 33
compounds (mainly toxic drugs) profiled in rat kidney (RK), rat liver (RL), primary rat and
human hepatocytes (RH and HH, respectively), obtained from Open TG-GATEs. This
resource was especially fitting our purpose, due to consistent experimental design across the
four target systems; TG-GATEs has been recently exploited to find hepatotoxic compounds
[54] and to compare rat liver testing systems [55]. We evaluated multiple ways to aggregate
these data for the description of drug-induced toxicity in human kidney and liver.
In our analysis, we chose maSigPro for modeling gene expression as it perfectly fits the
dynamic nature of the data (multiple time series). On the other hand, maSigPro selects signifi-
cantly different gene expression profiles based on two-step approach, in which genes that do
not pass the first step (for a given significance) will not be modeled in the next step (no P-value
and R2 calculated), meaning a worst possible rank in our case. This means that the com-
pound-wise gene lists are technically partially ranked lists. While this can be a problem for
standard rank-aggregation methods (as evident for the mean rank in the ROC analysis), the
alternative approaches RRA, Stuart and BIRRA were not specifically affected, making the pro-
posed method suitable for meta-analysis of partially ranked gene lists across compounds
obtained from literature.
There is a substantial level of gene filtering in our protocol, which was necessary to fairly
compare the rank-aggregation methods across species and with the literature-derived human
gene lists. The current method uses only one-to-one orthologs as defined in NCBI Homolo-
gene databases. Furthermore, the current approach for generating toxicity-related genes from
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annotated biomedical literature takes only into account human protein-coding genes. This
means that the results should improve by inclusion of more orthology relations (available in
other databases) as well as by extension of the literature-derived lists with toxicity related non-
coding human genes.
The differential expression analysis as well as the rank-aggregation analysis across drugs show
that in the in vitro model systems we get better coverage of the human gene candidates from the
literature as compared to the in vivo one. The highly imbalanced size of the sets of differentially
expressed genes seems to affect the mean aggregation method the most. Despite this, aggregation
of partial rankings is still capable to find common drug-response genes across all model systems.
An additional factor that could explain the better agreement to the in vitro models is the fact that
toxicity is often tested in cell lines and not in vivo. For example, around a 30% of references related
to the toxicity genes ATF3, GDF15, HMOX1 and EGR1 mentions also a cell line.
Another factor that could influence the differences between the ranks derived from the four
model systems for their agreement with the literature-derived lists could lie in the differences
in numbers of genes associated in the literature (which itself could reflect real physiological dif-
ferences). Accordingly, the lowest agreement found in RK could be related to the fact that the
number of literature-derived genes associated with kidney toxicity was much smaller than
those associated to liver toxicity. Both the HH and RH system recapitulated better the litera-
ture than RL, maybe indicating that the in vitro systems are more appropriate in general to
model liver toxicity. Unexpectedly, RH was a bit better than HH: while the similar perfor-
mance indicates that RH is a good model for studying liver toxicity, this result could be influ-
enced by the fact that studies dealing with human genes (among the selected PubMed abstracts
used for extraction of the literature-derived gene lists) might actually use rodent models.
Ranked lists for the four models, in vitro HH and RH, and in vivo RL and RK, indicated lit-
tle agreement in the top ranked genes (Table 1). Full rank comparisons (Fig 3) suggested that
the two rat hepatic models, RH and RL, are the most similar, while the two in vitro hepatocyte
models (HH and RH) follow next. Functional analysis, however, suggested that HH and RH
were the models more similar in terms of the functions of genes affected, mostly related to car-
boxylic acid metabolism.
Next, we combined the ranks looking for genes ranking high in the four models. Adding
pragmatically all ranks brings HMOX1, a very well-known toxicity associated gene to the top
position, and highlights a significant number of genes related to responses to toxicity and
chemical stimuli, suggesting that the addition of rankings is meaningful. Collectively, cell cycle
and cell division seem to be the processes most generally affected in the models. Rank compar-
ison between HH and RH highlights genes with astonishing different reactions to toxicity.
This suggest that researchers should not use RH as toxicity model if they are interested in cer-
tain genes related to human liver toxicity that react in HH but are non-responders in RH, such
as GSTP1. Similarly, our comparison of RH and RL indicates that while researchers interested
on toxic effects of genes related to lipid binding should be using hepatocytes, important toxic
effects on transporters that are observed in RL will be missed if using RH.
As every integrative approach that relies on multiple subsequent steps of data preprocess-
ing, modeling, and high-level summarization, our integration protocol can be influenced by
the limitations of each subsequent step of the analysis: from comprehensiveness of the input
(toxicogenomics) data, issues with data normalization and gene expression modeling, to speci-
ficity and sensitiveness of the method (maSigPro) to detected gene expression changes, the cri-
teria used for ranking (P-value and R2 of the gene-wise models) as well as the robustness of the
subsequent aggregation of gene lists (median of ranks, rank sum). However, the proposed pro-
tocol is fully flexible in the sense that each of the subsequent steps can be easily replaced with
suitable alternatives.
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Our approach to find literature derived genes also has some limitations. For example, we
missed PON1, which is known to be related to liver toxicity (see e.g., [56]). The reason is that
we used a conservative approach with stringent cut-offs in the selection of positives (see Meth-
ods for details).
Here we have presented a protocol for the aggregation and literature evaluation of toxicoge-
nomics data. Application to liver and kidney model systems of in vitro and in vivo toxicity
allowed us to define genes and pathways with general and particular toxicity related roles in
these models. We believe that this protocol should be easily applicable to other human organs
and to other models in toxicogenomics datasets.
Supporting information
S1 Fig. Dose-dependent summary of differential expression analysis. The distributions of
the number of differentially expressed genes are depicted with violin-plots by model systems,
with each dot representing the number of genes modulated by a single compound. Each row
corresponds to one dose level. The median and interquartile range of each distribution is
depicted by black dot and black bars respectively. Left column: full set of genes. Middle col-
umn: genes with rat ortholog. Right column: literature-derived genes.
(TIFF)
S2 Fig. Compound-specific distribution of differentially expressed gene set sizes. Each plot
corresponds to one compound (only high dose treatments results), with each dot correspond-
ing to the number of differentially expressed genes (all) obtained in a single model system
including the subset of genes having a rat otholog (othologs) and the subset found in the litera-
ture-derived lists (literature). The plots are grouped by the toxicity label of the compound: hep-
atotoxic in the first row, toxic for both organs in the second and the third row, and in the last
row we have few nephrotoxic and caffeine, not classified as a toxic compound.
(TIFF)
S3 Fig. Compound-specific AUC (ROC) performance across model systems. Each plot rep-
resents a single compound, depicting ROC curves for (compound-specific) model system-spe-
cific gene rankings (each color represents one model system), with literature-derived genes
used as positive examples. Curves are not smoothed, and the straight line fragments of the
curves result from the partial ranking (same lowest rank for all not-modulated genes, see
Methods for details). AUC (area under the ROC curve) values above 50% means better perfor-
mance than randomly assigned rank. The plots are grouped by the toxicity label of the com-
pound: hepatotoxic in the first row, toxic for both organs in the second and third row, and in
the last row we have few nephrotoxic and caffeine, not classified as a toxic compound.
(TIFF)
S1 File. Compounds and data samples summary. Excel file with description of the 33 com-
pounds profiled across all model systems in Open TG-GATEs database. The file includes full and
abbreviated names, and if available the toxicity labels, compound IDs in on-line compound data-
bases (PubChem and DrugBank), chemical structure description (by SMILES), mechanism, mode
of action as well as therapeutic labels. The file also includes a description of the array data used.
(XLSX)
S2 File. Literature-derived genes. Excel file with full lists of literature-derived organ-specific
toxicity-related genes, including the output of the co-occurrence analysis as well as the disease
enrichment of the organ-specific lists.
(XLSX)
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S3 File. Gene rankings. Excel file with all gene rankings (obtained by the different ranking
methods) for each model system in a separate data sheet. All data sheets are ranked according
to the finally chosen AR-ranking. The gene Entrez IDs and gene symbols correspond to the
human annotation space. Note that this file uses compound abbreviations introduced in S2
File.
(XLSX)
S4 File. Aggregation of AR ranks. Excel file with full gene list ranked according to the sum of
all model system-specific AR ranks. The gene Entrez IDs and gene symbols correspond to the
human annotation space. Extra columns include combinations of the AR rankings needed for
comparison between the modeled systems.
(XLS)
S5 File. Functional enrichment analysis of the top-100 HH ranked genes. Text file with the
output of a functional term enrichment analysis using the g:Profiler web tool for the top-100
HH ranked genes.
(TXT)
S6 File. Functional enrichment analysis of the top-100 RH ranked genes. Text file with the
output of a functional term enrichment analysis using the g:Profiler web tool for the top-100
RH ranked genes.
(TXT)
S7 File. Functional enrichment analysis of the top-100 RL ranked genes. Text file with the
output of a functional term enrichment analysis using the g:Profiler web tool for the top-100
RL ranked genes.
(TXT)
S8 File. Functional enrichment analysis of the top-100 RK ranked genes. Text file with the
output of a functional term enrichment analysis using the g:Profiler web tool for the top-100
RK ranked genes.
(TXT)
S9 File. Functional enrichment analysis for genes dys-regulated in the four model systems.
Text file with the output of a functional term enrichment analysis using the g:Profiler web tool
for the top-100 ranked genes according to the sum of the four rankings: HH, RH, RL, RK.
(TXT)
S10 File. Functional enrichment analysis for genes dys-regulated in human hepatocytes
but not in rat hepatocytes. Text file with the output of a functional term enrichment analysis
using the g:Profiler web tool for the top-100 ranked genes according to the difference between
the HH and the RH ranking.
(TXT)
S11 File. Functional enrichment analysis for genes dys-regulated in rat hepatocytes but not
in human hepatocytes. Text file with the output of a functional term enrichment analysis
using the g:Profiler web tool for the top-100 ranked genes according to the difference between
the RH and the HH ranking.
(TXT)
S12 File. Functional enrichment analysis for genes dys-regulated in rat liver but not in rat
hepatocytes. Text file with the output of a functional term enrichment analysis using the g:
Profiler web tool for the top-100 ranked genes according to the difference between the RL and
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the RH ranking.
(TXT)
S13 File. Functional enrichment analysis for genes dys-regulated in rat hepatocytes but not
in rat liver. Text file with the output of a functional term enrichment analysis using the g:Pro-
filer web tool for the top-100 ranked genes according to the difference between the RH and the
RL ranking.
(TXT)
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